- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.20 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x ZN: ZINC ION(Non-covalent)
- 2 x MG: MAGNESIUM ION(Non-covalent)
- 2 x 9GJ: N-{(1S)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Mikami, S. et al., Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders. J. Med. Chem. (2017)
- Release Date
- 2017-08-23
- Peptides
- cGMP-dependent 3',5'-cyclic phosphodiesterase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
C